Lantheus is merging with Curium in an $8B deal to create a global radiopharmaceutical leader with expanded reach across oncology, neurology, and cardiology in 70+ countries. This merger represents significant value creation and portfolio diversification.
Company is under investigation for potential securities law violations and breach of fiduciary duties related to its $102.50 per share sale to Curium US Holdings LLC, with contingent value rights that may not adequately compensate shareholders.
Lantheus shareholders receive a significant premium (38% to 60-day VWAP) with certain cash consideration of $102.50 per share plus potential upside through CVRs tied to commercial milestones. The Board unanimously approved the transaction as value-maximizing after a comprehensive strategic review.
Mixed results with modest revenue growth (4.0% Q4, 0.5% FY) but declining PYLARIFY sales (-9.7% Q4, -6.5% FY) offset by strategic acquisitions and pipeline expansion. Positive forward guidance and multiple FDA approvals expected in 2026, but the divestiture of legacy SPECT business and shift in strategy suggest operational restructuring. Adjusted EPS growth of 4.7% in Q4 is modest, and full-year adjusted EPS declined from $6.76 to $6.08.
The article is primarily an announcement of an earnings call and webcast with no forward-looking statements or performance indicators. While the SPECT business sale closure is mentioned, it lacks detail on financial impact or strategic implications, making this a routine corporate announcement without clear positive or negative implications.
Articles that tag LNTH but are mainly about other companies.
Listed as a major key player in the competitive landscape but no specific recent developments or achievements mentioned in the article.
Collaborating with Eli Lilly on Lu-PNT2002, a promising third-line radioligand therapy candidate in the robust emerging pipeline.
Specialized radiopharmaceutical company positioned to benefit from market expansion driven by rising cancer cases and nuclear medicine adoption.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
